Business Wire

BEARINGPOINT-REGTECH

17.6.2021 09:52:11 CEST | Business Wire | Press release

Share
BearingPoint RegTech and Vizor Software Join Forces: Global RegTech and SupTech Powerhouse Created

BearingPoint RegTech (“RegTech”), a leading European provider of innovative regulatory, risk, and supervisory technology solutions, has signed an agreement regarding the acquisition of Vizor Software (“Vizor”). Vizor is a global leader in regulatory and supervisory technology headquartered in Dublin, Ireland. With the newly formed partnership, RegTech and Vizor aim to accelerate their future growth journey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005052/en/

The combination of the two companies follows a clear strategic rationale as the companies fit perfectly together and complement each other ideally with their solution portfolios. RegTech and Vizor have a strong track record within the regulatory and supervisory technology space. Furthermore, the two companies serve complimentary geographies. While RegTech can rely on a strong customer base in Germany, Austria and Switzerland and a growing presence in adjacent geographies such as Benelux, Ireland, the Nordics, and the UK, Vizor’s customers are primarily based in Africa, Asia, Australia, Canada, and Middle East.

As part of one group, RegTech and Vizor are well positioned for further growth. The group will provide innovative regulatory, risk, and supervisory technology solutions to all stakeholders across the regulatory value chain. The combined organization will maximize synergies in product development and innovation to create even more value for their customers.

Together, RegTech and Vizor serve more than 7,000 firms including banks, insurance companies, and financial services providers with reporting solutions. At the same time, they enable more than 50 regulators and tax authorities to collect and analyze data from 34,000 firms in 60 countries.

Jürgen Lux, CEO of BearingPoint RegTech, states: “The deal with Vizor is an important milestone in RegTech's development. It demonstrates that we are growing strongly as a stand-alone company since Nordic Capital came onboard as our new owner late last year. Both Vizor and RegTech have over 20 years of history, are market leaders with our RegTech and SupTech solutions, and complement each other perfectly in terms of products, markets, and customers. As a combined company, we will develop a strategy for further, sustainable growth to fulfill our shared mission: to contribute to the transparency and stability of the financial markets with our solutions.”

Conor Crowley, CEO at Vizor Software, comments: “Since we founded Vizor over 20 years ago, we have made the company a renowned technology provider for central banks, regulators and tax authorities around the world. Vizor’s decision to join forces with RegTech is crucial for the further development and international growth of our company. We look forward to opening a new chapter together with RegTech not only in the history of our company, but also in the field of RegTech and SupTech.”

Emer FitzPatrick, Country Lead Ireland at BearingPoint RegTech, adds: “As Country Lead Ireland, I am particularly excited about the combination of RegTech and Vizor. Our Irish team will now not only be part of a large international RegTech provider, but also part of a larger organization in Ireland. We look forward to working with the management and entire team at Vizor, with whom we share not only a very similar vision and mission, but also cultural values.”

The current management team at Vizor will remain and work in close partnership with RegTech. The sellers were advised by Novacies Capital (M&A) and Eversheds Sutherland (Legal).

The transaction is subject to customary regulatory approvals. The parties involved have agreed not to disclose further details of the transaction.

About Vizor
Vizor Software is a global leader in regulatory and supervisory technology, trusted across over 30 countries worldwide. Using their experience of over 20 years in the industry, the company operates within three areas: SupTech for Financial Regulators, RegTech for regulatory reporting across Banking, Insurance, and Pensions as well as cross-border Automated Exchange of Information (AEOI) for Tax Authorities. Since the foundation in the year 2000, Vizor Software has been developed and shaped to serve the evolving needs of competent authorities around the world. Ready for market since the end of 2014, the Vizor AEOI solution has become the world’s leading solution for Tax Authorities. Vizor is headquartered in Dublin, Ireland, and has a total workforce of approximately 100 employees.

For more information, please visit: www.vizorsoftware.com

About BearingPoint RegTech
BearingPoint RegTech is a leading international provider of innovative regulatory, risk, and supervisory technology solutions (RegTech, RiskTech, and SupTech), of tax reporting products, as well as of services along the Regulatory Value Chain for financial services. Customers representing 6,000 firms worldwide, among them large international banks, a major part of the largest European banks, leading insurance companies as well as supervisory authorities and central banks, trust BearingPoint RegTech’s products and services. BearingPoint RegTech works closely with regulators and, as a member of standardization bodies such as XBRL, actively contributes to the standard-setting process. BearingPoint RegTech combines regulatory know-how with a proven, reliable, and forward-looking RegTech solution suite, advisory, managed services, and training seminars. BearingPoint RegTech is headquartered in Frankfurt, Germany, and has a total workforce of approximately 650 employees.

For more information, please visit: www.reg.tech

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye